Background/Purpose: To determine the correlation between SLE-specific and generic patient reported outcomes measures (PROs), and to examine their associations with patients’ global rating of change (GRC) in their health-related quality of life (HRQoL), and Lupus Low Disease Activity State (LLDAS).

Methods: SLE patients who full-filled either the 1997 ACR or the 2012 SLICC classification criteria, and attended a rheumatology clinic in Thailand between 2013 and 2017, were recruited for this study. They completed the SLEQoL-TH and SF36-TH surveys (Thai versions), and rated their GRC compared to their previous visit using a 7-point Likert scale (GRC -7 to +7) on the same day of clinic visits. Based on GRC scores, patients were categorised as ‘no change’ (-1 to +1), ‘deterioration’ (-2 to -7) or ‘improvement’ (+2, to +7) in HRQoL. SLE disease activity was determined by the SLEDAI-2K. Physician global assessment (PGA) of disease activity was rated 0-3. LLDAS was defined as described (Franklyn K. Ann Rheum Dis 2016). Correlation between SLEQoL-TH and SLF36-TH was examined using Person’s correlation coefficients. Associations of GRC and LLDAS with SLEQoL-TH/SF36-TH surveys were examined using generalised estimating equations.

Results: 337 patients (2,062 visits) were included. Median [inter-quartile range (IQR)] values of patients’ age at enrolment, disease duration, and study duration was 37 [28, 48] years, 7 [3, 13] years, and 3.18 [1.55, 3.46] years, respectively. 56% of patients experienced at least one flare. Median [IQR] time adjusted mean (TAM) -SLEDAI and TAM-PGA scores were 3.5 [2.0, 5.6] and 0.4 [0.3, 0.7], respectively. During the study, 81% of patients achieved LLDAS at least once, and were in LLDAS in approximately 50%. TAM SLEQoL-TH score, and SF36-TH physical component summary (PCS) and mental component summary (MCS), were 89.8 [81.7, 94.9], 46.8 [42.0, 52.1] and 49.4 [42.9, 55.0], respectively. SLEQoL-TH total scores correlated significantly with both SF36-TH PCS and MCS scores (r = 0.55 and 0.60, respectively, p < 0.01). Patients who were in LLDAS had statistically significantly higher scores in both SLEQoL-TH and SF36-TH surveys when compared to patients who were not in LLDAS. Patients reported improvement in 58%, deterioration in 15% and no change in HRQoL in 27% of all visits. Compared to the ‘no change’ control group, patients who reported deterioration in HRQoL were significantly less likely to be in LLDAS (OR 0.53, 95% CI: 0.39-0.72, p<0.001), but HRQoL improvement was not associated with significant increased likelihood of LLDAS. The PGA showed a weak association with the GRC (r = -0.14).

Conclusion: The SLE specific PRO, SLEQoL-TH, correlated significantly with the generic PRO, SF36-TH. LLDAS was associated with better HRQoL, and improving HRQoL was predictive for LLDAS attainment.

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-between-sle-specific-and-generic-health-related-quality-of-life-surveys-and-their-association-with-patient-global-rating-of-change-and-lupus-low-disease-activity-state-a-longitudinal-stu/